GRT-R902

DRUG3 trials

Sponsors

Gritstone bio, Inc., Seattle Project Corporation

Conditions

Colonic NeoplasmsColorectal CancerColorectal NeoplasmsGastroesophageal AdenocarcinomaNon Small Cell Lung CancerUrothelial Carcinoma

Phase 1

A Study of a Personalized Neoantigen Cancer Vaccine

CompletedNCT03639714

Gritstone bio, Inc.Colorectal Cancer, Gastroesophageal Adenocarcinoma, Non Small Cell Lung Cancer +1

Start: 2019-02-13End: 2022-11-10Updated: 2023-09-13

Phase 2

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruitingNCT05141721

Seattle Project CorporationColorectal Neoplasms

Start: 2022-02-12End: 2027-03-31Target: 700Updated: 2025-05-16

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

WithdrawnNCT05456165

Gritstone bio, Inc.Colonic Neoplasms, Colorectal Neoplasms

Start: 2022-05-19End: 2022-09-01Updated: 2024-12-31

Related Papers

A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC).

Journal of Clinical Oncology2025-01-274 citations

Abstract 1126: Disease monitoring with comprehensive genomics provides evidence of mechanism of action and immune evasion in patients receiving an individualized neoantigen cancer vaccine

Cancer Research2023-04-04

660 Clinicopathologic characteristics of patients with metastatic colorectal cancer with molecular responses following treatment with an individualized neoantigen vaccine regimen

Regular and Young Investigator Award Abstracts2022-11-01

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.

2022-08-15167 citations

Abstract 1238: Comprehensive ctDNA monitoring provides early signal of clinical benefit with a novel personalized neoantigen directed immunotherapy for late-stage cancer patients

Cancer Research2022-06-151 citations

Abstract 4159: Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses

Cancer Research2022-06-151 citations

Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).

Journal of Clinical Oncology2022-06-0114 citations

Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.

Journal of Clinical Oncology2020-05-208 citations